 |
|
|
| |
Switching from Efavirenz/Emtricitabine/Tenofovir DisoproxilFumarate(EFV/FTC/TDF) Single Tablet
Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir
DisoproxilFumarate(FTC/RPV/TDF) STR
in VirologicallySuppressed, HIV-1 Infected Subjects
|
| |
| |
Reported by Jules Levin EACS Belgrade Oct 12-15 2011
C Cohen,1A Mills,2E DeJesus,3B Rashbaum,4
C Brinson,5K Yale,6S Ramanathan,6H Wang,6
A Jandourek,6and A Cheng6
1Community Research Initiative, Boston, MA ; 2Anthony Mills MD Inc, Los Angeles, CA; 3Orlando Immunology Ctr, Orlando, FL; 4Capital Medical Associates, Washington, DC; 5Central Texas Clinical Research, Austin, TX; 6Gilead Sciencesnc., Foster City, CA
|
| |
|
|
|
|
|
